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Background: Several studies have investigated a pos-
sible association between respiratory infection and 
acute myocardial infarction (MI). As both influenza 
and pneumococcal infections are vaccine prevent-
able, understanding the populations affected by virus-
induced cardiovascular complications is important to 
guide public health and clinical practice. Aim: This 
observational study aimed to quantify the associa-
tion between laboratory-confirmed respiratory bacte-
ria or virus infections and risk of first MI or stroke, by 
using self-controlled case series (SCCS) analysis of 
anonymised linked electronic Danish health records.
Methods: The SCCS method was used to determine the 
relative incidence of the first event of MI and stroke 
occurring within 28 days after laboratory-confirmed 
respiratory infections compared with the baseline 
time period. Results: In the age and season adjusted 
analyses for first acute MI, the incidence ratios (IR) of 
a MI event occurring during the risk period were sig-
nificantly elevated following a Streptococcus pneumo-
niae  infection with values of 20.1, 11.0 and 4.9 during 
1–3, 4–7 and 8–14 days, respectively and following 
respiratory virus infection with values of 15.2, 4.5 and 
4.4 during 1–3, 8–14 and 15–28 days, respectively. The 
significantly elevated IRs for stroke following an  S. 
pneumoniae  infection were 25.5 and 6.3 during 1–3 
and 8–14 days, respectively and following respiratory 
virus infection 8.3, 7.8 and 6.2 during 1–3, 4–7 and 
8–14 days, respectively. Conclusion: This study sug-
gested a significant cardiovascular event triggering 
effect following infection with  S. pneumoniae  and 
respiratory viruses (mainly influenza), indicating the 
importance of protection against vaccine-preventable 
respiratory infections.
Introduction
The leading causes of death worldwide for the past 
15 years were ischaemic heart disease and stroke [1], 
which is also the case in Denmark ( http://www.health-
data.org/denmark ). An association between circulation 
of seasonal influenza and acute cardiovascular events 
was first suggested in the 1930s, although these find-
ings were limited by risk of ecological bias and lack 
of control for potential confounding factors [2]. A sys-
tematic review from 2009 found that influenza, mostly 
defined by clinical symptoms alone, appeared to trigger 
acute myocardial infarction and death from cardiovas-
cular disease [3] and a meta-analysis of case–control 
studies from 2015 also found a significant association 
between recent respiratory infection and acute myocar-
dial infarction [4]. Kwong et al. [5] used a laboratory-
confirmed influenza virus infection as exposure and 
found an association with acute myocardial infarction 
in a Canadian population.
Whether other respiratory organisms might act as trig-
gers for cardiovascular events was investigated in a 
time series analysis using population-level data from 
England. This study showed a significant association 
between the timing of different laboratory-confirmed 
respiratory viral infections and myocardial infarc-
tion and ischaemic stroke hospitalisations among 
older people. The respiratory viruses investigated 
included adenovirus, human metapneumovirus, influ-
enza virus, respiratory syncytial virus and rhinovirus 
[6]. These findings were supported by self-controlled 
case-series analyses of Scottish individuals, in which 
incidence ratios (IR) for myocardial infarction and 
stroke were significantly raised following laboratory-
confirmed  Streptococcus pneumoniae  and influenza 
virus infections, and raised point estimates were 
also observed following other laboratory-confirmed 
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respiratory virus infections [7]. A systematic review and 
meta-analysis of observational studies concluded that 
major cardiac complications occurred in a substantial 
proportion of the patients with community-acquired 
pneumonia, which can be caused by a range of patho-
gens [8]. Currently both influenza virus and pneumo-
coccal infections are vaccine preventable and several 
vaccines against respiratory syncytial virus are in the 
pipeline [9]. However influenza and pneumococcal 
vaccine uptake is sub-optimal across much of Europe. 
Understanding the relative effects of different organ-
isms on cardiovascular complications as well as the 
populations affected, will help to inform research into 
interventions and guide prevention strategies.
Denmark has well-functioning national electronic 
health registries, including the microbiology data-
base (MiBa) which allows real-time sharing of micro-
biological test results nationwide and integrates into 
the national eHealth infrastructure [10]. We aimed 
to test whether previous findings on cardiovascular 
events triggering effects of laboratory-confirmed res-
piratory pathogens also applied to a different north-
ern European population than that of England and 
Scotland. The aim of our study was to quantify the 
association between laboratory-confirmed respiratory 
bacteria or virus infections and risk of first myocardial 
infarction or stroke using self-controlled case series 
(SCCS) analysis of anonymised linked electronic health 
records from Denmark.
Methods
Study design
We used the SCCS method to estimate the relative inci-
dence of myocardial infarction and stroke following 
laboratory-confirmed respiratory infections compared 
with baseline time periods [11] –  Figure 1. The SCCS 
method is best suited for acute events and transient 
exposures [12]. Only individuals who have a record 
of exposure (diagnosed with a respiratory infection) 
and an outcome (myocardial infarction or stroke) were 
included. The comparisons were made within individu-
als, implying that factors constant over time cancel out, 
i.e. that there is implicit control for fixed confounding 
factors. Factors that varied over time such as age and 
season were accounted for in the analysis. The study 
period was 1 January 2010 to 31 December 2016.
Following the time of a respiratory infection symptom 
onset, which was approximated by the date a sample 
had been taken for laboratory confirmation, a 28 day 
risk period was considered. Time outside the 28 day 
window was counted as baseline. The 28 day risk period 
was further divided into four periods, 1 to 3 days, 4 to 7, 
8 to 14 and 15 to 28 days (Figure 1). These periods were 
chosen for the purpose of direct comparison with other 
studies. Fourteen days before and the day of sampling 
were considered as pre-exposure period and excluded 
from the baseline period, because being diagnosed 
with an acute myocardial infarction or stroke during 
this time may change the likelihood of being sampled 
and diagnosed with a respiratory infection. The SCCS 
methods compares the likelihood of an acute myocar-
dial infarction or stroke during the risk periods (after a 
laboratory-confirmed respiratory infection) to the like-
lihood outside the risk periods (baseline) within a per-
son. Comparing the incidence risk between two time 
periods gives a relative incidence risk.
Figure 1
Illustration of the self-controlled case series study methoda used in the study, Denmark, 1 January 2010−31 December 2016
AMI/stroke
Respiratory sample dateb
BASELINE   28 days
1 January 2010
31 December 2016
STUDY PERIOD BEGINS
STUDY PERIOD ENDS
Baseline
Pre-exposure period
Post infection risk period (days)
1–3 days
4–7 days
8–14 days
15–28 days
RISK PERIOD
BASELINE
AMI: acute myocardial infarction.
a Modified after Petersen et al. [12].
b The date when the sample is taken approximates the date of symptom onset of a respiratory infection.
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Data sources
The Civil Registration System
The Danish Civil Registration System (CRS) was estab-
lished on 1 April 1968 and since then a unique per-
sonal identification number has been assigned to all 
Danish residents. CRS contains continuously updated 
information on vital status and permanent residence in 
Denmark. From CRS, information on birthdate, sex and 
vital status were extracted.
Danish National Patient Register
The Danish National Patient Register (DNPR) contains 
information on all hospital admissions and outpatient 
treatments in Denmark [13]. Date of admission and 
discharge are available for each registration in DNPR. 
We used date of admission as date of diagnosis for 
the acute myocardial infarction or stroke. All disease 
diagnoses are classified according to World Health 
International Statistical Classification of Diseases and 
Health-related Problems, 10th Revision (ICD-10) [14].
Danish Microbiology database
The Danish Microbiology database (MiBa) was initiated 
in January 2010 and includes all microbiological test 
results from all the departments of clinical microbiol-
ogy in Denmark. Each registration contains information 
on sample date, laboratory analysis and test result [10]. 
Both records of respiratory virus infections and inva-
sive pneumococcal disease infections were extracted 
from MiBa. Individuals could be swabbed at a general 
practitioner’s office, or at a hospital.
Pneumococcal laboratory database at Statens Serum 
Institut
In Denmark, the national surveillance of invasive pneu-
mococcal disease (IPD) has been centralised at Statens 
Serum Institut (SSI) since 1938. All clinical microbiol-
ogy departments in Denmark submit IPD isolates for 
serotype determination to the National Neisseria and 
Streptococcus Reference Laboratory (NSR) at SSI.
Data extraction and linking
All the above registries contain patients’ information 
under their respective unique personal identification 
number from CRS, which can be used for record link-
age as described below.
Hospital admissions for first acute myocardial infarc-
tion (ICD-10 codes: I21 and I23) and/or stroke (ICD-10 
codes: I60, I61 and I63) in individuals aged 40 years 
and above during the study period 1 January 2010 to 
31 December 2016 were extracted from the DNPR. In 
the SCCS method, repeated events must be independ-
ent. The risk of a subsequent event may change after 
experiencing either a myocardial infarction or stoke. 
We therefore applied a 10 year look back from 1 January 
2000 to 31 December 2009 to identify individuals who 
had hospital admissions for acute myocardial infarc-
tion or stroke before the study period.
Specimens testing positive for any of the following 
viruses from 1 January 2010 to 31 December 2016 were 
extracted from MiBa: human metapneumovirus, influ-
enza virus, parainfluenza virus, respiratory syncyt-
ial virus, or rhinovirus. During the same time period, 
specimens testing positive for  S. pneumoniae  were 
extracted from MiBa and the pneumococcal database 
Figure 2
Individuals included in the study, Denmark, 1 January 2010–31 December 2016 (n = 1,350 individuals)
This left 618 with MI.
606 individuals left for
the analysis.
1,199 individuals with MI 
and respiratory infection.
1,205 individuals with stroke
and respiratory infection.
This left 752 individuals with 
stroke.
744 individuals left for
the analysis.
451 individuals with stroke were excluded
because the first diagnosis occurred
during the 10 years look-back period.
Two individuals were diagnosed with 
stroke after death and excluded.
Four individuals diagnosed with stroke 
had both S. pneumoniae (n = 4) and a 
viral respiratory infection (n = 4) during 
the study period and were excluded.
581 individuals with MI were excluded 
because the first diagnosis occurred 
during the 10 years look-back period.
Six individuals diagnosed with MI had 
both S. pneumoniae (n = 6) and a viral 
respiratory infection (n = 6) during the 
study period and were excluded.
A. Myocardial infarction B. Stroke
MI: myocardial infection; S. pneumoniae: Streptococcus pneumoniae.
Ten individuals, six with MI and four with stroke, had a dual viral-bacterial infection. Each of them appeared on the two data files with viral 
and bacterial pathogens simultaneously, so their numbers were excluded twice.
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at SSI. For each individual, laboratory detection of the 
same virus infection or pneumococcal infection within 
28 days was considered the same infection, and only 
the earliest infection was considered for this study.
We used deterministic linkage to link data from DNPR 
to MiBa data and the pneumococcal laboratory data 
through the unique personal identification number. 
Only individuals aged 40 years and above and who 
were diagnosed with both an event (myocardial infarc-
tion or stroke) and with at least one of the respiratory 
infections during the study period were included in the 
study. Vital status from the CRS registry was linked to 
the data to identify individuals who died at any point 
during the study period. Individuals could enter the 
study on 1 January 2010 or when they reached 40 years 
of age after that date and exit the study at death or at 
31 December 2016. The 40 year lower age limit for inclu-
sion in the study was chosen for comparability to other 
studies using a similar approach [6,7].
Statistical analysis
We investigated the relative incidence of a first myo-
cardial infarction or stroke occurring within 28 days 
after the beginning of laboratory-confirmed respiratory 
infections with  S. pneumoniae, human metapneumo-
virus, influenza virus, parainfluenza virus, respiratory 
syncytial virus, or rhinovirus as compared with the 
baseline time period for each individual using condi-
tional Poisson regression.
The time dependent variables such as age and sea-
son are not accounted for in the basic SCCS method, 
but can be included in the model [11]. Age was con-
trolled for in 5-year bands (40–44, 45–49, 50–54, 
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85–89, 
90–94, 95–99,100–104). Seasons were categorised 
as 3-month bands, repeated to span the study period 
(Jan–Mar, Apr–Jun, Jul–Sep, Oct–Dec).
Individuals experiencing acute myocardial infarction 
or stroke have an increased risk of dying. In the SCCS 
method, experiencing the outcome event should not 
censor follow-up, but this assumption can be violated 
for fatal cardiovascular events, which may lead to bias 
in either direction [12]. We therefore performed a sen-
sitivity analysis, where individuals who died within 
30 days following an acute myocardial infarction or 
stroke were excluded from the analysis to investigate 
this potential bias.
Table 1
Descriptive statistics of individuals ≥ 40 years old with first myocardial infarction or stroke and at least one respiratory 
infection, Denmark, 1 January 2010–31 December 2016 (n = 1,350)
Characteristics
Myocardial infarction Stroke
n % n %
Sex
Female 253 41.7 347 46.6
Age group in years at first cardiovascular event 
40–49 40 6.6 35 4.7
50–59 95 15.7 91 12.2
60–69 156 25.7 211 28.4
70–79 175 28.9 216 29.0
80–89 121 20.0 152 20.4
≥ 90 19 3.1 39 5.2
Total 606 100 744 100
Stratified age in years at first cardiovascular event
40–64 210 34.7 214 28.8
≥ 65 396 65.3 530 71.2
Total 606 100 744 100
Mortality
Mortality ≤ 30 days after cardiovascular event 51 8.4 88 11.8
Mortality during study period 242 39.9 336 45.2
Total 606 100 744 100
Laboratory-confirmed respiratory infection episodesa,b
Streptococcus pneumoniae 222 35.4 332 43.3
Respiratory virusc 406 64.6 434 56.7
Total 628 100 766 100
a Myocardial infarction individuals and multiple samples: one individual has four viral samples, one individual has three viral samples and 12 
individuals have two viral samples. Five individuals have two bacterial samples.
b Stroke individuals and multiple samples: three individuals have three viral samples, six individuals have two viral samples. One individual 
has three bacterial samples and eight individuals have two bacterial samples.
c Human metapneumovirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or rhinovirus.
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To investigate the potential effect modification of age 
on the association between respiratory infections and 
myocardial infarction/stroke, age was stratified on 
40–64 years and ≥ 65 years [7].
Data extraction and linking of data were performed 
using SAS version 9.4 [15]. STATA version 13 [16] was 
used for the SCCS analyses.
Ethical statement
No ethical approval was required for this register-
based study
Results
From 2000 to 2016, a total of 1,199 individuals with 
acute myocardial infarction and 1,205 individuals with 
stroke who also were diagnosed with either a S. pneu-
moniae or a viral respiratory infection were identified. 
Among these respectively, 581 with acute myocardial 
infarction (48%) and 451 individuals with stroke (37%), 
were excluded because their first acute myocardial 
infarction/stroke diagnosis occurred during the 10 year 
look-back period. This left 618 with acute myocardial 
infarction and 754 individuals with stroke who also had 
either a S. pneumoniae or a viral respiratory infection. 
When combining information on bacterial and viral 
respiratory infections, six individuals diagnosed with 
acute myocardial infarction and four diagnosed with 
stroke had both S. pneumoniae and a viral respiratory 
infection during the study period. Because the current 
study aimed to estimate the relative incidence of 
acute myocardial infarction and stroke separately for 
bacterial and viral infections, these individuals were 
excluded. Moreover, because the records with the two 
types of pathogens appeared on two different data 
files (i.e. bacterial or viral), these patients had each 
been counted twice among the respective 618 and 754 
individuals with acute myocardial infection or stroke; 
this was accounted for when removing the records. In 
addition, two individuals were diagnosed with stroke 
after the date of death and excluded from the analy-
sis. This left 606 individuals for the acute myocardial 
infarction analysis and 744 individuals for the stroke 
analysis (Figure 2 and Table 1).
Among the 606 individuals diagnosed with acute myo-
cardial infarction, 628 respiratory infection episodes 
were detected. Of these, 406 infections were due to 
respiratory viruses with an average of 1.04 episodes per 
individual (range: 1–4 per individual), and 222 infec-
tions were due to  S. pneumoniae  with an average of 
1.02 episodes per individual (range: 1–2 per individual) 
(Table 1).
Among the 744 individuals diagnosed with stroke, a 
total of 766 laboratory-confirmed respiratory infec-
tions were detected during the study period. Of the 
766 corresponding samples, 434 samples contained 
respiratory viruses with an average of 1.03 episodes 
per individual (range: 1–3 per individual), while 332 
samples contained  S. pneumoniae  with an average of 
1.03 episodes per individual (range: 1–3 per individual) 
(Table 1).
All in all, among individuals with acute myocar-
dial infarction the proportion of women was 41.7%, 
while among individuals with stroke this was 46.6%. 
Individuals diagnosed with acute myocardial infarc-
tion appeared to be younger with 34.7% (210/606) 
aged 40–64 years compared with 28.8% (214/744) for 
Table 2
Age and season adjusted incidence ratio for first acute myocardial infarction (n = 606 individuals) and first stroke (n = 744 
individuals) in periods after Streptococcus pneumoniae, respiratory viruses (combined) and influenza infections compared 
with baseline time, Denmark, 1 January 2010–31 December 2016
Days after sample 
collectiona
Streptococcus pneumoniae Respiratory virusesb (combined) Influenza
Eventsc 
 
(n)
IR (CI 95%) p value
Eventsc 
 
(n)
IR (CI 95%) p value
Eventsc 
 
(n)
IR (CI 95%) p value
Myocardial infarction
1–3 6 20.1 (8.9–45.8)  < 0.001 8 15.2 (7.5–31.1)  < 0.001 8 17.5 (8.5–36.2)  < 0.001
4–7 4 11.0 (4.1–29.8) < 0.001 3 4.5 (1.4–14.0) 0.010 3 5.1 (1.6–16.3) 0.005
8–14 3 4.9 (1.6–15.6) 0.006 5 4.4 (1.8–10.8) 0.001 3 3.1 (1.0–9.7) 0.056
15–28 0 ND ND 4 1.9 (0.7–5.1) 0.205 3 1.7 (0.5–5.3) 0.374
Baseline Ref 1 (ref) NA Ref 1 (ref) NA Ref 1 (ref) NA
Stroke
1–3 12 25.5 (14.2–45.8) < 0.001 5 8.3 (3.4–20.2) < 0.001 5 10.3 (4.2–25.4) < 0.001
4–7 2 3.5 (0.9–14.1) 0.079 6 7.8 (3.4–17.5) < 0.001 4 6.5 (2.4–17.7) < 0.001
8–14 6 6.3 (2.8–14.4) < 0.001 8 6.2 (3.0–12.6) < 0.001 6 5.9 (2.6–13.4) < 0.001
15–28 16 9.2 (5.5–15.4) < 0.001 5 2.0 (0.8–4.9) 0.119 2 1.0 (0.3–4.2) 0.956
Baseline Ref 1 (ref) NA Ref 1 (ref) NA Ref 1 (ref) NA
CI: confidence interval; IR: incidence ratio; NA: not applicable; ND: could not be estimated (not determined); ref: reference.
a The sample collection time approximates the time of symptom onset of the respiratory infection.
b Human metapneumovirus, influenza virus, parainfluenza virus, respiratory syncytial virus and rhinovirus.
c Events of first acute myocardial infarction or stroke.
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those with stroke. The observed mortality in this study, 
overall, and within 30 days post-cardiovascular event, 
seemed highest among stroke individuals 45.2% and 
11.8%, respectively, as compared with acute myocar-
dial infarction individuals 39.9% and 8.4%, respec-
tively (Table 1).
In the age and season adjusted analyses for first 
acute myocardial infarction, the IRs were significantly 
elevated 1–14 days following infections with  S. pneu-
moniae  and respiratory viruses as compared with the 
baseline period (Table 2). The IRs for acute myocar-
dial infarction following an  S. pneumoniae  infection 
were 20.1, 11.0 and 4.9 during 1–3, 4–7 and 8–14 days, 
respectively. The IRs for acute myocardial infarction 
following a respiratory virus infection were 15.2, 4.5 
and 4.4 during 1–3, 4–7 and 8–14 days, respectively.
In the age and season adjusted analyses for first stroke, 
the IRs of a stroke occurring during the risk period were 
significantly elevated 1–28 days following infection 
with S. pneumoniae except for the time period 4–7 days. 
The IRs for stroke following an S. pneumoniae infection 
were 25.5, 3.5, 6.3 and 9.2 during 1–3, 4–7, 8–14 and 
15–28 days, respectively. The IRs for stroke following a 
respiratory virus infection were significantly elevated 
1–14 days and the IRs were 8.3, 7.8 and 6.2 during 1–3, 
4–7 and 8–14 days, respectively (Table 2).
In the age and season adjusted sub-analyses for first 
acute myocardial infarction and stroke where only 
influenza virus infections were included, the estimated 
IRs were similar to the IRs obtained in the analysis 
including all respiratory virus infections (Table 2).
Excluding those who died within 30 days
In total 51 (8.4%) and 88 (11.8%) individuals died 
within 30 days after acute myocardial infarction and 
stroke, respectively (Table 1). Excluding those who 
died within 30 days after an event provided results that 
were mostly unchanged from the main analysis (Table 
3), although with slightly attenuated effect estimates. 
Using the risk period 1–3 days as an example, the acute 
myocardial infarction IR after  S. pneumoniae  infection 
changed from 20.1 to 18.2 and for respiratory viruses 
the IR changed from 15.2 to 14.8. The stroke IR after S. 
pneumoniae  infection changed from 25.5 to 21.9 and 
for respiratory virus the change was from 8.3 to 7.9.
Stratifying by age
For both acute myocardial infarction and stroke, the 
number of Individuals aged between 40 and 64 years of 
age covered approximately one third of the total number 
of individuals included in the main analyses, for some 
risk periods no events were observed and IR could not 
be estimated. In addition, several IR estimates had 
wide confidence intervals. In particular the estimated 
IRs for the 1–3 days risk periods appeared to be higher 
in the 40–64 years age stratified analyses compared 
with what we observed in the main analysis (Table 2). 
Following onset of an  S. pneumoniae  infection, the 
acute myocardial infarction IR was 37.1 and for stroke 
the IR was 43.3 during the 1–3 days risk period among 
40–64 year olds. In the 1–3 days after onset of a res-
piratory virus infection, the acute myocardial infarction 
IR was 5.1 and non-significant while during the same 
period the stroke IR was 16.4 and significant (Table 4). 
IRs for all risk periods are shown in Table 4. For the age 
group ≥ 65 years the acute myocardial infarction and 
stroke IRs were similar to the IR estimates observed 
Table 3
Age and season adjusted incidence ratio for first acute myocardial infarction (n = 555) and first stroke (n = 656) after 
excluding patients who died within 30 days of Streptococcus pneumoniae and respiratory viruses infections (combined) 
compared with baseline time, Denmark, 1 January 2010–31 December 2016
Days after sample collectiona
Streptococcus pneumoniae Respiratory virusesb (combined)
IR (CI 95%) p value IR (CI 95%) p value
Myocardial infarction
1–3 18.2 (7.4–44.6)  < 0.001 14.8 (6.9–31.6)  < 0.001
4–7 11.4 (4.2–30.9) < 0.001 4.9 (1.6–15.4) 0.006
8–14 3.4 (0.8–13.6) 0.090 3.9 (1.4–10.4) 0.008
15–28 ND ND 2.0 (0.8–5.5) 0.157
Baseline 1 (ref) NA 1 (ref) NA
Stroke
1–3 21.9 (10.7–44.6) < 0.001 7.9 (2.9–21.2) < 0.001
4–7 2.2 (0.3–15.9) 0.425 7.6 (3.1–18.5) < 0.001
8–14 7.8 (3.5–17.7) < 0.001 6.2 (2.9–13.3) < 0.001
15–28 9.6 (5.5–16.6) < 0.001 1.4 (0.4–4.4) 0.564
Baseline 1 (ref) NA 1 (ref) NA
CI: confidence interval; IR: incidence ratio; NA: not applicable; ND: could not be estimated; ref: reference.
a The sample collection time approximates the time of symptom onset due to infection with either Streptococcus pneumoniae or respiratory 
viruses.
b Human metapneumovirus, influenza virus, parainfluenza virus, respiratory syncytial virus and rhinovirus.
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in the main analyses. Acute myocardial infarction and 
stroke IRs for all risk periods are shown in Table 4. 
Discussion
We found that the IRs of first acute myocardial infarction 
and stroke were markedly elevated following infections 
with  S. pneumoniae  and selected respiratory viruses 
(mainly influenza virus) compared with baseline time 
periods using national linked records from Denmark. 
The elevated IRs were observed during the risk periods 
1–14 days following infection, except for the stroke IRs 
following S. pneumoniae infection where an elevated IR 
was observed during the whole risk period apart from 
the 4–7 day period.
The IR patterns observed during the risk periods in 
our study were similar to the patterns observed in 
the Scottish and Canadian studies with the highest 
IRs observed 1–3 days after infection followed by a 
decrease in IRs with increasing time since infection 
[5,7]. The estimated IRs were in general higher in our 
study compared with the Scottish and Canadian studies 
in particular during the risk window 1–3 days following 
infection. The IRs for acute myocardial infarction fol-
lowing  S. pneumoniae and respiratory virus infections 
in the Scottish study were 5.98 and 5.59, respectively 
1–3 days following infection, compared with 20.1 and 
15.2 in our study. The IRs for acute myocardial infarc-
tion 1–3 days following influenza infection were 9.8 
in the Scottish study [7], 6.3 in the Canadian study [5] 
and 17.5 in our study. The IR for stroke in the Scottish 
study was 12.3 following  S. pneumoniae  infection 
and 6.79 following infection with respiratory viruses 
during the 1–3 days risk window. In our study, the 
corresponding IRs were 25.5 and 8.3. In the Scottish 
study, acute myocardial infarction and stroke IRs were 
higher following influenza infections compared with 
other respiratory viruses. In our study, the sample size 
of other viruses than influenza only accounted for 20% 
of all respiratory viruses; therefore, due to the small 
Table 4
Age and season adjusted incidence ratio for first acute myocardial infarction (n = 606) and first stroke (n = 744) stratified 
by age 40–64 years and ≥ 65 years in periods after Streptococcus pneumoniae and respiratory viruses infections (combined) 
compared with baseline time, Denmark, 1 January 2010–31 December 2016
Days after sample collectiona
Streptococcus pneumoniae Respiratory virusesb (combined)
IR (CI 95%) p value IR (CI 95%) p value
Myocardial infarction
40–64 years (n = 210)
1–3 37.1 (8.7–158.3) < 0.001 5.1 (0.7–36.6) 0.108
4–7 14.6 (2.0–108.7) 0.009 7.6 (1.9–31.2) 0.005
8–14 ND ND 2.2 (0.3–16.1) 0.426
15–28 ND ND 1.2 (0.2–8.4) 0.880
Baseline 1 (ref) NA 1 (ref) NA
≥ 65 years (n = 396)
1–3 16.1 (5.5–47.2) < 0.001 21.1 (9.8–45.6) < 0.001
4–7 10.7 (3.2–35.0) < 0.001 2.4 (0.3–17.3) 0.381
8–14 6.2 (1.9–20.5) 0.003 5.9 (2.1–16.0) 0.001
15–28 ND ND 2.4 (0.8–7.6) 0.134
Baseline 1 (ref) NA 1 (ref) NA
Stroke
40–64 years (n = 214)
1–3 43.3 (15.3–122.5) < 0.001 16.4 (5.1–52.89) < 0.001
4–7 NA NA 8.4 (2.0–34.7) 0.003
8–14 10.3 (2.5–43.2) 0.001 10.4 (3.7–28.9) < 0.001
15–28 14.1 (5.5–36.1) < 0.001 ND ND
Baseline 1 (ref) NA 1 (ref) NA
≥ 65 years (n = 530)
1–3 20.6 (10.1–42.3) < 0.001 4.9 (1.2–20.0) 0.025
4–7 4.3 (1.1–17.4) 0.041 7.7 (2.9–21.0) < 0.001
8–14 5.3 (1.9–14.2) 0.001 4.6 (1.7–12.5) 0.003
15–28 7.9 (4.2–14.7) < 0.001 3.0 (1.2–7.4) 0.016
Baseline 1 (ref) NA 1 (ref) NA
CI: confidence interval; IR: incidence ratio; NA: not applicable; ND: could not be estimated (no events); ref: reference.
a The sample collection time approximates the time of symptom onset due to infection with either Streptococcus pneumoniae or respiratory 
viruses.
b Human metapneumovirus, influenza virus, parainfluenza virus, respiratory syncytial virus and rhinovirus.
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sample size, it was not possible to make a similar 
comparison based on Danish data.
In the Scottish study, the estimated IRs for the effect of 
respiratory viruses were generally higher among indi-
viduals aged 40–64 years compared with those aged 
≥ 65 years, and this was suggested to possibly be due 
to a higher influenza vaccine coverage among those 
aged ≥ 65 years [7]. In our study, the IRs associated with 
respiratory viruses were not in general higher among 
individuals below 65 years old, although confidence 
intervals were wide. However, the IRs for myocardial 
infarction and stroke 1–3 days following  S. pneumo-
niae infection in the age group 40–64 years were more 
than double those of the age group ≥ 65 years. Based 
on the assumption that the pneumococcal vaccine 
may reduce the risk of cardiac outcomes, either by pre-
venting infection or lessening its severity, this might 
indicate that individuals aged ≥ 65 years are aware 
of getting their recommended pneumococcal vac-
cine. A similar pattern was observed for stroke in the 
Scottish study [7]. However, the differences between 
the age strata observed in the Scottish study and ours 
require further investigation and it would be interest-
ing to repeat the analysis with a larger sample size 
stratifying on influenza and S. pneumoniae vaccination 
status. Additionally analyses with stratifications based 
on influenza and pneumococcal subtypes, as well 
as taking into account the underlying comorbidities 
individuals may have, may provide knowledge allowing 
to further customise/target the influenza and pneumo-
coccal vaccination programmes.
Acute myocardial infarction and stroke are related to a 
high mortality rate, which can result in a shortening of 
the observation period leading to bias in either direc-
tion [12]. In both the Scottish [7] and in our study, the 
estimated IRs when excluding those who died within 
30 days after the event produced results similar to the 
main analysis indicating that the high mortality did not 
bias the results (Table 2 and 3).
Individuals ≥ 65 years and people at any age diagnosed 
with cardiovascular risk factors where an influenza 
infection can result in severe health effects can get 
the influenza vaccine for free in Denmark. However, 
they might not be aware that they have increased risk 
of acute myocardial infarction and stroke following an 
influenza infection. Genetic changes or differences in 
the circulating influenza viruses compared with the 
vaccine strains in some seasons can result in low or 
suboptimal vaccine effectiveness [17], however, in 
these seasons improvement of influenza vaccine cov-
erage will still increase number of prevented influenza 
cases. S. pneumoniae  is also vaccine preventable and 
the vaccine is recommended to individuals ≥ 65 years, 
but in Denmark only individuals with very high risk of 
invasive pneumococcal disease (IPD) are covered by 
limited subsidy when vaccinated [18]. However there 
are other groups with increased risk of IPD where pneu-
mococcal vaccination is recommended but not free of 
charge e.g. all individuals ≥ 65 years of age who do not 
have an IPD risk classified as very high [19,20]; indi-
viduals of all ages diagnosed with chronic conditions 
such as heart disease and lung disease [21,22].
Strengths of our study include (i) use of SCCS analysis 
which implicitly controls for fixed between-person con-
founding effects and is statistically efficient compared 
with a cohort design, (ii) use of laboratory-confirmed 
infections from a national microbiology database com-
bined with ICD-10 coded cardiovascular outcomes, 
which are shown to have high positive predictive val-
ues in validation studies from Denmark [23-25] that 
enhance confidence in the validity of measurements, 
(iii) use of national linked data across all of Denmark 
and (iv) use of the same protocol as the Scottish study 
to allow for direct comparisons between the studies. 
Although our study period was shorter and the sample 
size smaller than the Scottish one, the main results 
obtained by the two studies are comparable.
Our study also has limitations. With a sample size of 
606 individuals in the acute myocardial infarction anal-
yses, and 744 in the stroke analyses, totalling 1,350 
individuals our study was smaller than the Scottish 
study [7], which resulted in lack of power in some 
sub-group analyses. In addition, there were too few 
non-influenza respiratory viruses to separate the res-
piratory virus analyses according to influenza vs non-
influenza viruses, and the limited sample size and the 
short duration of the time series did not enable us to 
disentangle influenza subtypes effects. Only very few 
individuals experienced co-infections and the effect 
of co-infections could not be investigated separately. 
For the respiratory infections we used date of sampling 
and not date of symptom onset, which means that 
the true date of infection occurred during the 14 days 
excluded from the analyses. The IRs decreased as time 
since sampling increased. The fact that we use date of 
sampling, which is after the date of infection, may lead 
to underestimation of the effect. The decision to swab 
an individual to verify a respiratory infection might be 
more likely for individuals with a severe infection or 
underlying risk factors for severe disease, which might 
indicate that the results from this study apply to more 
severe infections and/or vulnerable patients [5].
In conclusion, this study suggested a significant car-
diovascular event triggering effect following infection 
with  S. pneumoniae  and respiratory viruses (mainly 
influenza). This was found not only in the age group 
≥ 65 years, but also among 40–64 year olds. The results 
were similar to those found in a Scottish population 
using the same study protocol, suggesting that they 
are generalisable across different northern European 
populations. These findings indicate the importance 
to inform general practitioners and individuals at risk 
of cardiovascular diseases about the importance of 
being protected against vaccine-preventable respira-
tory infections.
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